Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Moleculin Biotech, Inc. (MBRX) had Return on Equity of -65.89% for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-7.96M |
|
-- |
|
-- |
|
$7.56M |
|
$-7.56M |
|
$-0.07M |
|
$-7.63M |
|
$-7.63M |
|
$-7.63M |
|
$-7.63M |
|
$-7.63M |
|
$-7.63M |
|
$-7.56M |
|
$-7.55M |
|
5.68M |
|
5.68M |
|
$-1.40 |
|
$-1.40 |
|
| Balance Sheet Financials | |
$8.72M |
|
$0.06M |
|
$12.36M |
|
$21.09M |
|
$9.31M |
|
-- |
|
$0.19M |
|
$9.50M |
|
$11.59M |
|
$0.44M |
|
$11.59M |
|
7.10M |
|
| Cash Flow Statement Financials | |
$-12.77M |
|
-- |
|
$11.22M |
|
$8.88M |
|
$7.26M |
|
$-1.62M |
|
$0.82M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.94 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-12.77M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-65.89% |
-1739.18% |
|
-36.21% |
|
-65.89% |
|
$1.63 |
|
$-2.25 |
|
$-2.25 |
|